NVSEF News and Press, Novartis Ag Basel Akt From 10/27/20

Novartis AG (NVS) Q3 2020 Earnings Conference Call October 27, 2020 08:50 AM ET Company Participants Samir Shah - Global Head, Investor Relations Vas Narasimhan - Chief Executive Officer Harry Kirsch - Chief Financial Officer Marie-France Tschudin - President, Novartis Pharmaceuticals Susanne...

NLS Pharmaceutics has filed to raise $20 million in a U.S. IPO. The firm is advancing treatments for narcolepsy and ADHD. NLSP is thinly capitalized and has made no apparent progress on beginning trials for its lead candidate, so I'll pass on the IPO. For further details see...

Foghorn Therapeutics has filed to raise $120 million in a U.S. IPO. The firm is developing treatments for ocular cancer and other cancers. FHTX is still at a preclinical stage of development, so the IPO may be more suited to long-term hold institutional investors. For furthe...

ClearBridge is a leading global asset manager committed to active management. Research-based stock selection guides our investment approach, with our strategies reflecting the highest-conviction ideas of our portfolio managers. Extreme concentration of the largest stocks in the benchm...

Opthea has filed proposed terms to raise capital from a U.S. IPO. The firm is developing a treatment for Wet AMD and other eye conditions. OPT has produced impressive Phase 2b efficacy trial results for its lead candidate, so the IPO is worth considering for long-term hold life sc...

InMed Pharmaceuticals has filed proposed terms for its uplisting / Nasdaq IPO. The firm is researching cannabis-derived treatments for skin and eye conditions. INM is still at a preclinical stage of development, so the offering may be more suited to long-term hold institutional in...

Shattuck Labs has filed terms for its U.S. IPO. The firm is advancing a pipeline of treatment candidates for ovarian and other cancers. STTK has produced impressive results in early trials, has a significant collaboration with Takeda Pharmaceuticals and the IPO appears reasonably ...

Shattuck Labs has filed to raise development capital in a U.S. IPO. The firm is advancing drug treatment candidates for various cancer conditions. STTK has shown promising early trial results and has a strong collaboration partner in Takeda Pharmaceuticals. For further detai...

Virios Therapeutics has filed to raise $30 million in an IPO of its common stock. The firm is developing a proprietary formulation for the treatment of fibromyalgia, a pain condition. VIRI has achieved intriguing early efficacy results, received fast track review status and the IP...

Quick Take Taysha Gene Therapies ( TSHA ) has filed to raise $125 million in an IPO of its common stock, according to an S-1 registration statement . The company is developing genetic therapy treatments for various neurodegenerative diseases and other disorders. TSHA is still at a precl...